文献速递头颈与中枢神经肿瘤

达拉非尼联合曲美替尼治疗BRAFV600E突变中枢神经系统肿瘤:Drug Rediscovery Protocol结果

BRAFV600E-mutated central nervous system tumors benefit from treatment with dabrafenib plus trametinib: Results from the Drug Rediscovery Protocol.
PubMed 文献 · Eur J Cancer · 2026-03-11

本研究评估达拉非尼联合曲美替尼在BRAFV600E突变进展或复发中枢神经系统肿瘤成人患者中的疗效与安全性。30例患者入组,25例可评估,临床获益率76%,客观缓解率44%,中位缓解持续时间27.8个月,中位无进展生存18.1个月,中位总生存32.3个月,未观察到意外毒性。

要点

  • 达拉非尼联合曲美替尼在BRAFV600E突变CNS肿瘤中临床获益率达76%
  • 客观缓解率44%,中位缓解持续时间27.8个月
  • 中位无进展生存18.1个月,中位总生存32.3个月

核心结论

  • 达拉非尼联合曲美替尼对复发或进展的BRAFV600E突变CNS肿瘤高度有效,是这类脆弱患者的有价值治疗选择。

研究设计与样本

  • Drug Rediscovery Protocol(2023-509152-33-00)中评估达拉非尼150 mg每日两次联合曲美替尼2 mg每日一次治疗成人BRAFV600E突变CNS肿瘤(包括毛细胞型星形细胞瘤、多形性黄色星形细胞瘤和胶质母细胞瘤),直至疾病进展或不可耐受毒性。
  • 2019年1月至2024年5月共30例患者开始治疗,其中25例完成至少一个完整治疗周期后可评估疗效。
  • 主要终点为临床获益(确认的完全或部分缓解或稳定疾病≥16周)和安全性。

主要发现

  • 临床获益见于19例患者,包括11例确认的部分缓解和8例稳定疾病≥16周,临床获益率76%(95% CI,54.9%-90.6%)。
  • 客观缓解率44%(95% CI,24.4%-65.1%)。
  • 中位随访40.2个月后,中位缓解持续时间27.8个月(95% CI,23.6个月-未达到)。
  • 中位无进展生存18.1个月(95% CI,8.4个月-未达到),中位总生存32.3个月(95% CI,22.0个月-未达到)。
  • 未观察到意外毒性。

临床怎么用

  • 对于BRAFV600E突变的复发或进展中枢神经系统肿瘤成人患者,可考虑达拉非尼联合曲美替尼治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Dual MAPK pathway inhibition with dabrafenib and trametinib has demonstrated significant activity across several BRAFV600E-mutated tumor types. The aim of this study was to evaluate the efficacy and safety of dabrafenib plus trametinib in patients with BRAFV600E-mutated progressive or recurrent tumors of the central nervous system (CNS). METHODS: Adult patients with BRAFV600E-mutated CNS-tumors, including pilocytic astrocytoma, pleomorphic xanthoastrocytoma, and glioblastoma, progressive on their last treatment line, were treated in the Drug Rediscovery Protocol (2023-509152-33-00) with dabrafenib 150 mg twice daily plus trametinib 2 mg once daily, until disease progression or intolerable toxicity. The primary endpoints were clinical benefit (CB: confirmed complete or partial response [PR] or stable disease [SD] ≥ 16 weeks) and safety. RESULTS: Between January 2019 and May 2024, 30 patients started treatment, of whom 25 were evaluable for response after completing at least one full treatment cycle. CB was observed in 19 patients, including 11 with confirmed PR and eight with SD for ≥ 16 weeks, resulting in a CB-rate of 76% (95% CI, 54.9%-90.6%) and an objective response rate of 44% (95% CI, 24.4%-65.1%). After a median follow-up of 40.2 months, the median duration of response was 27.8 months (95% CI, 23.6 months-not reached). The median progression-free and overall survival were 18.1 months (95% CI, 8.4 months-not reached) and 32.3 months (95% CI, 22.0 months-not reached), respectively. No unexpected toxicities were observed. CONCLUSIONS: Dabrafenib plus trametinib is highly effective in patients with recurrent or progressive BRAFV600E-mutated CNS-tumors, representing a valuable therapeutic option for these vulnerable patients.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Haj Mohammad SF, Spiekman IAC, Verkerk K, et al. BRAFV600E-mutated central nervous system tumors benefit from treatment with dabrafenib plus trametinib: Results from the Drug Rediscovery Protocol. Eur J Cancer. 2026. PMID: 41830662. doi:10.1016/j.ejca.2026.116674

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。